13 results on '"Stein, David A."'
Search Results
2. Compassionate Use of REGEN-COV® in Patients With Coronavirus Disease 2019 (COVID-19) and Immunodeficiency-Associated Antibody Disorders.
- Author
-
Stein, David, Oviedo-Orta, Ernesto, Kampman, Wendy A, McGinniss, Jennifer, Betts, George, McDermott, Margaret, Holly, Beth, Lancaster, Johnathan M, Braunstein, Ned, Yancopoulos, George D, and Weinreich, David M
- Subjects
- *
CHRONIC disease risk factors , *THERAPEUTIC use of monoclonal antibodies , *INFECTION risk factors , *REVERSE transcriptase polymerase chain reaction , *COVID-19 , *IMMUNOGLOBULINS , *VIRAL load , *RETROSPECTIVE studies , *QUANTITATIVE research , *IMMUNOLOGICAL deficiency syndromes , *RISK assessment , *TREATMENT effectiveness , *QUALITATIVE research , *DESCRIPTIVE statistics , *DRUG side effects , *PATIENT safety - Abstract
Background Patients with immunodeficiency-associated antibody disorders are at a higher risk of prolonged/persistent COVID-19 infection, having no viable treatment options. Methods A retrospective analysis of patients with primary and/or secondary immunodeficiency-associated antibody disorders who received casirivimab and imdevimab (REGEN-COV®) under emergency compassionate use. Objective were to describe safety and response to REGEN-COV, focusing on the subset of patients who had COVID-19 duration ≥21 days before treatment. Results Quantitative (change in oxygenation status and/or viral load) and/or qualitative (physician-reported clinical status) outcomes data are reported from 64 patients. Improvement in ≥1 outcome was observed in 90.6% of the overall patient group. Thirty-seven of these had COVID-19 duration ≥21 days before treatment; median time from diagnosis to REGEN-COV treatment was 60.5 days. Of the 29 patients with COVID-19 duration ≥21 days before treatment and available outcome data, 96.6% showed improvement in ≥1 outcome. In the 14 patients with post-treatment reverse transcription–polymerase chain reaction (RT-PCR) results available, 11 (78.6%) reported a negative RT-PCR following treatment, with 5 (45.5%) and 8 (72.7%) patients reporting a negative RT-PCR within 5 days and 21 days of treatment, respectively. Ten of 85 patients (11.8%) experienced serious adverse events; only one was an infusion-related reaction, possibly related to REGEN-COV. Two deaths were reported; neither were attributed to REGEN-COV. Conclusions In this retrospective analysis of immunodeficient patients granted REGEN-COV under emergency compassionate use, REGEN-COV treatment was associated with rapid viral clearance and clinical improvement in patients with longstanding COVID-19. Adverse events were consistent with COVID-19 and its associated complications, and due to patients' concurrent medical conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Structural signatures: a web server for exploring a database of and generating protein structural features from human cell lines and tissues.
- Author
-
Zatorski, Nicole, Stein, David, Rahman, Rayees, Iyengar, Ravi, and Schlessinger, Avner
- Subjects
- *
INTERNET servers , *CYTOSKELETAL proteins , *CELL lines , *TISSUES , *DATABASES , *LUNG cancer - Abstract
Structural features of proteins provide powerful insights into biological function and similarity. Specifically, previous work has demonstrated that structural features of tissue and drug-treated cell line samples can be used to predict tissue type and characterize drug relationships, respectively. We have developed structural signatures, a web server for annotating and analyzing protein features from gene sets that are often found in transcriptomic and proteomic data. This platform provides access to a structural feature database derived from normal and disease human tissue samples. We show how analysis using this database can shed light on the relationship between states of single-cell RNA-sequencing lung cancer samples. These various structural feature signatures can be visualized on the server itself or downloaded for additional analysis. The structural signatures server tool is freely available at https://structural-server.kinametrix.com/. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Do Viruses From Managed Honey Bees (Hymenoptera: Apidae) Endanger Wild Bees in Native Prairies?
- Author
-
Pritchard, Zoe A, Hendriksma, Harmen P, Clair, Ashley L St, Stein, David S, Dolezal, Adam G, O'Neal, Matthew E, and Toth, Amy L
- Subjects
APIDAE ,HYMENOPTERA ,HONEYBEES ,BEES ,BUMBLEBEES ,BEEKEEPING ,PRAIRIES - Abstract
Populations of wild and managed pollinators are declining in North America, and causes include increases in disease pressure and decreases in flowering resources. Tallgrass prairies can provide floral resources for managed honey bees (Hymenoptera: Apidae, Apis mellifera Linnaeus) and wild bees. Honey bees kept near prairies may compete with wild bees for floral resources, and potentially transfer viral pathogens to wild bees. Measurements of these potential interactions are lacking, especially in the context of native habitat conservation. To address this, we assessed abundance and richness of wild bees in prairies with and without honey bee hives present, and the potential spillover of several honey bee viruses to bumble bees (Hymenoptera: Apidae, Bombus Latrielle). We found no indication that the presence of honey bee hives over 2 yr had a negative effect on population size of wild bee taxa, though a potential longer-term effect remains unknown. All levels of viruses quantified in bumble bees were lower than those observed in honey bees. Higher levels of deformed wing virus and Israeli acute paralysis virus were found in Bombus griseocollis DeGeer (Hymenoptera: Apidae) collected at sites with hives than those without hives. These data suggest that the presence of honey bees in tallgrass prairie could increase wild bee exposure to viruses. Additional studies on cross-species transmission of viruses are needed to inform decisions regarding the cohabitation of managed bees within habitat utilized by wild bees. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino oligomers.
- Author
-
Rosenke, Kyle, Leventhal, Shanna, Moulton, Hong M, Hatlevig, Susan, Hawman, David, Feldmann, Heinz, and Stein, David A
- Subjects
SARS-CoV-2 ,CELL culture ,COVID-19 ,OLIGOMERS ,ANTIVIRAL agents ,NUCLEOTIDE sequence - Abstract
Background: As the causative agent of COVID-19, SARS-CoV-2 is a pathogen of immense importance to global public health. Development of innovative direct-acting antiviral agents is sorely needed to address this virus. Peptide-conjugated morpholino oligomers (PPMO) are antisense compounds composed of a phosphorodiamidate morpholino oligomer covalently conjugated to a cell-penetrating peptide. PPMO require no delivery assistance to enter cells and are able to reduce expression of targeted RNA through sequence-specific steric blocking.Methods: Five PPMO designed against sequences of genomic RNA in the SARS-CoV-2 5'-untranslated region and a negative control PPMO of random sequence were synthesized. Each PPMO was evaluated for its effect on the viability of uninfected cells and its inhibitory effect on the replication of SARS-CoV-2 in Vero-E6 cell cultures. Cell viability was evaluated with an ATP-based method using a 48 h PPMO treatment time. Viral growth was measured with quantitative RT-PCR and TCID50 infectivity assays from experiments where cells received a 5 h PPMO treatment time.Results: PPMO designed to base-pair with sequence in the 5' terminal region or the leader transcription regulatory sequence region of SARS-CoV-2 genomic RNA were highly efficacious, reducing viral titres by up to 4-6 log10 in cell cultures at 48-72 h post-infection, in a non-toxic and dose-responsive manner.Conclusions: The data indicate that PPMO have the ability to potently and specifically suppress SARS-CoV-2 growth and are promising candidates for further preclinical development. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
6. Cognitive Stimulation and Cognitive and Functional Decline in Alzheimer's Disease: The Cache County Dementia Progression Study.
- Author
-
Treiber, Katherine A., Carlson, Michelle C., Corcoran, Chris, Norton, Maria C., Breitner, John C. S., Piercy, Kathleen W., DeBerard, Michael Scott, Stein, David, Foley, Beth, Welsh-Bohmer, Kathleen A., Frye, Amber, Lyketsos, Constantine G., and Tschanz, JoAnn T.
- Published
- 2011
- Full Text
- View/download PDF
7. Inhibition of Japanese encephalitis virus replication in cultured cells and mice by a peptide-conjugated morpholino oligomer.
- Author
-
Anantpadma, Manu, Stein, David A., and Vrati, Sudhanshu
- Subjects
- *
JAPANESE encephalitis viruses , *VIRAL replication , *OLIGOMERS , *GENE expression , *ANTIVIRAL agents , *FLAVIVIRUSES - Abstract
Background: Japanese encephalitis virus (JEV) has a significant impact on public health throughout Asia, and there is a pressing need for development of new therapeutics against it. Methods: Peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) are antisense agents that enter cells readily and interfere with gene expression. Four PPMOs, targeting various locations in the JEV genome, were evaluated for antiviral activity against JEV in cultured cells and the mouse model of JEV infection. Results: A PPMO (P10882) targeting the JEV 3′ cyclization sequence (3′CSI) had significant antiviral activity in Vero (epithelial), Neuro2A (neuronal) and J774E (macrophage) cells at concentrations that were not cytotoxic. P10882 added before infection suppressed JEV replication to an undetectable level in Vero cells and produced a 93% and 66% reduction in titre in J774E and Neuro2A cells, respectively, when measured at 24 h postinfection. In uninfected cells, fluorescein-labelled PPMOs entered J774E cells most efficiently, followed by Vero and Neuro2A cells. The antiviral effect of P10882 was also demonstrated in vivo, where 60%-80% of 1-week-old mice treated intracerebrally with a 20 mg/kg dose of P10882 every 12 h for 5 days were protected from a lethal dose of JEV and showed an undetectable level of virus in brain tissue at 2 days post-infection. Conclusions: P10882, which targets sequence that is highly conserved across members of the JEV serocomplex, was previously shown to be effective in a mouse model of West Nile disease, and represents a candidate antiviral agent against members of the JEV serocomplex. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
8. A Randomized Study of the Use of Fluconazole in Continuous versus Episodic Therapy in Patients with Advanced HIV Infection and a History of Oropharyngeal Candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40.
- Author
-
Goldman, Mitchell, Cloud, Gretchen A., Wade, Karen D., Reboli, Annette C., Fichtenbaum, Carl J., Hafner, Richard, Sobel, Jack D., Powderly, William G., Patterson, Thomas F., Wheat, Lawrence J., Stein, David K., Dismukes, William E., and Filler, Scott G.
- Subjects
HIV infections ,CANDIDIASIS ,CLINICAL trials ,HIV-positive persons ,THERAPEUTICS ,MYCOSES - Abstract
Background. In human immunodeficiency virus (HIV)-infected patients, fluconazole prophylaxis is associated with reductions in the rate of fungal infection. However, concerns exist with regard to the use of fluconazole prophylaxis and the risk of development of fluconazole treatment-refractory infections. Methods. We performed a randomized, open-label trial that compared oral fluconazole given continuously (200 mg 3 times weekly', the "continuous fluconazole arm") with fluconazole that was provided only for episodes of orophayngeal candidiasis (OPC) or esophageal candidiasis (EC) (the "episodic fluconazole arm") in HIV-infected persons with CD4
+ T cell counts of <150 cells/mm³ and a history of OPC. The primary study end point was the time to development of fluconazole-refractory OPC or EC, which was defined as lack of response to 200 mg fluconazole given daily for 14 or 21 days, respectively. Results. A total of 413 subjects were randomized to receive continuous fluconazole, and 416 were randomized to receive episodic fluconazole. After 42 months, 17 subjects (4.1%) in the continuous fluconazole arm developed fluconazole-refractory OPC or EC infections, compared with 18 subjects (4.3%) in the episodic fluconazole arm, with no difference between treatment arms with regard to the time to development of a fluconazole-refractory infection within 24 months (P = .88, by log-rank test) or before the end of the study (P = .97, by the log-rank test). Continuous fluconazole therapy was associated with fewer cases of OPC or EC (0.29 vs. 1.08 episodes per patient-year; P <.0001) and fewer invasive fungal infections (15 vs. 28 episodes; P = .04, by χ² test), but not with improved survival, compared with episodic fluconazole therapy. Conclusion. Continuous fluconazole therapy is not associated with significant risk of fluconazole-refractory OPC or EC, compared with episodic fluconazole therapy, in HIV-infected patients with access to active antiretroviral therapy. [ABSTRACT FROM AUTHOR]- Published
- 2005
9. Developmentally regulated transporter in Leishmania is encoded by a family of clustered genes.
- Author
-
Stein, David A., Cairns, Bradley R., and Landfear, Scott M.
- Published
- 1990
10. Immunogenicity of Two Doses of Yeast Recombinant Hepatitis B Vaccine in Healthy Older Adults.
- Author
-
Gellin, Bruce G., Greenberg, Richard N., Hart, Richard H., Bertino, Joseph S., Stein, David H., Deloria, Maria A., and Clements-Mann, Mary Lou
- Abstract
To determine the immunogenicity of two doses of yeast recombinant hepatitis B virus (HBV) vaccine containing surface (S) protein, an open-label, multicenter trial was conducted in 199 healthy HBV-seronegative adults ⩾40 years old. Volunteers were randomly assigned to 1 of 5 groups to receive a total of three 10-µg doses, at 0, 1, and 6 months, or a total of two doses of 20 µg and 10 µg, 20 µg and 20 µg, 40 µg and 10 µg, or 40 µg and 20 µg at 0 and 6 months. The 40-µg/20-µg regimen elicited the highest rate of seroprotection (96.2%), with a geometric mean titer of antibody against the S protein of 369 mIU/mL, not significantly different from the 536 mIU/mL achieved with three doses. These results suggest that a two-dose regimen can achieve seroprotection similar to that of the three-dose regimen. Whether a shorter interval can be used or a booster dose will be needed later to confer durable immunity are unknown. [ABSTRACT FROM PUBLISHER]
- Published
- 1997
11. Cytoplasts Generate Oxidants but Require Added Neutrophil Granule Constituents for Fungicidal Activity against Candida albicans Hyphae.
- Author
-
Stein, David K., Malawista, Stephen E., Van Blaricom, Gretchen, Wysong, Deborah, and Diamond, Richard D.
- Abstract
Killing of Candida albicans hyphae requires oxidant generation by neutrophils (PMNL), but it is uncertain whether hyphal killing is mediated by PMNL oxidants alone or requires contributions by granule constituents. This was assessed using U-cytoplasts (U-CYT), anucleate PMNL fragments depleted of cytoplasmic granules but retaining motility and respiratory burst activity. Granule-depleted U-CYT killed Staphylococcus aureus, but hyphae remained viable despite targeted generation of putatively fungicidal oxidants by avidly adherent U-CYT. Hyphal killing occurred by combining U-CYT with sublethal concentrations of purified PMNL granule extracts approximating those present in equivalent numbers of intact PMNL. Contributions of granule constituents were not entirely attributable to purified granule constituents with known antimicrobial activity (lactoferrin, cathepsin G, myeloperoxidase, and human neutrophil peptide defensins 1–3) individually or combined. Thus, oxidant generation by intact PMNL may be necessary but not always sufficient to mediate hyphal killing without complementary nonoxidative mechanisms. [ABSTRACT FROM PUBLISHER]
- Published
- 1995
- Full Text
- View/download PDF
12. Persistence of HIV Drug Resistance Mutations: More Clues from Clinical Observations.
- Author
-
Jenny-Avital, Elizabeth R. and Stein, David K.
- Subjects
- *
LETTERS to the editor , *DRUG resistance - Abstract
Presents a letter to the editor about the persistence of HIV drug resistance mutations.
- Published
- 2004
- Full Text
- View/download PDF
13. Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus.
- Author
-
David A. Stein, Claire Y.-H. Huang, Shawn Silengo, Adams Amantana, Stacy Crumley, Robert E. Blouch, Patrick L. Iversen, Richard M. Kinney, Stein, David A, Huang, Claire Y-H, Silengo, Shawn, Amantana, Adams, Crumley, Stacy, Blouch, Robert E, Iversen, Patrick L, and Kinney, Richard M
- Subjects
GEL permeation chromatography ,CHROMATOGRAPHIC analysis ,SEPHAROSE ,RODENTS - Abstract
Objectives: To determine the antiviral activity of phosphorodiamidate morpholino oligomers (PMO) and peptide-conjugated PMO (PPMO) in AG129 mice infected with dengue 2 virus (DENV-2).Methods: Antisense PMO and PPMO were designed against the 5' terminal region (5'SL) or the 3'-cyclization sequence region (3'CS) of DENV genomic RNA and administered to AG129 mice before and/or after infection with DENV-2. In addition, cell culture evaluations designed to determine optimum PPMO length, and pharmacokinetic and toxicity analysis of PPMO were also carried out.Results: Mock-treated AG129 mice lived for 9-17 days following intraperitoneal (ip) infection with 10(4)-10(6) pfu of DENV-2 (strain New Guinea C). Intraperitoneal administration of 5'SL or 3'CS PPMO before and after DENV infection produced an increase in the average survival time of up to 8 days. Animals receiving only post-infection PPMO treatment did not benefit significantly. Cell culture studies showed that PPMO of 22-24 bases long produced substantially higher DENV titre reductions than did PPMO that were either shorter or longer. Pharmacokinetic and toxicology analysis with non-infected animals showed that nine consecutive once-daily ip treatments of 10 mg/kg PPMO resulted in high concentrations of PPMO in the liver and caused little impact on overall health.Conclusions: The data indicate that PPMO had considerable antiviral efficacy against DENV-2 in the AG129 mouse model and that PPMO treatment early in the course of an infection was critical to extending the survival times of DENV-2-infected mice in the AG129 model system. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.